201 related articles for article (PubMed ID: 23546553)
21. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
Ingle JN; Schaid DJ; Goss PE; Liu M; Mushiroda T; Chapman JA; Kubo M; Jenkins GD; Batzler A; Shepherd L; Pater J; Wang L; Ellis MJ; Stearns V; Rohrer DC; Goetz MP; Pritchard KI; Flockhart DA; Nakamura Y; Weinshilboum RM
J Clin Oncol; 2010 Nov; 28(31):4674-82. PubMed ID: 20876420
[TBL] [Abstract][Full Text] [Related]
22. Polypharmacy, over-the-counter medications, and aromatase inhibitor adherence in early-stage breast cancer.
Joyce E; Tao X; Stearns V; Hayes DF; Storniolo AM; Kidwell KM; Henry NL
Breast Cancer Res Treat; 2024 Apr; 204(3):539-546. PubMed ID: 38198070
[TBL] [Abstract][Full Text] [Related]
23. Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging.
Morales L; Pans S; Paridaens R; Westhovens R; Timmerman D; Verhaeghe J; Wildiers H; Leunen K; Amant F; Berteloot P; Smeets A; Van Limbergen E; Weltens C; Van den Bogaert W; De Smet L; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2007 Jul; 104(1):87-91. PubMed ID: 17061044
[TBL] [Abstract][Full Text] [Related]
24. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
[TBL] [Abstract][Full Text] [Related]
25. Aromatase inhibitors and musculoskeletal pain in patients with breast cancer.
Winters L; Habin K; Gallagher J
Clin J Oncol Nurs; 2007 Jun; 11(3):433-9. PubMed ID: 17623627
[TBL] [Abstract][Full Text] [Related]
26. Association of CYP19A1 gene variations with adjuvant letrozole-induced adverse events in South Indian postmenopausal breast cancer cohort expressing hormone-receptor positivity.
Umamaheswaran G; Kadambari D; Muthuvel SK; Kalaivani S; Devi J; Damodaran SE; Pradhan SC; Dubashi B; Dkhar SA; Adithan C
Breast Cancer Res Treat; 2020 Jul; 182(1):147-158. PubMed ID: 32385792
[TBL] [Abstract][Full Text] [Related]
27. Rheumatoid arthritis and aromatase inhibitors.
Bertolini E; Letho-Gyselinck H; Prati C; Wendling D
Joint Bone Spine; 2011 Jan; 78(1):62-4. PubMed ID: 20621535
[TBL] [Abstract][Full Text] [Related]
28. An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.
Barnadas A; Estévez LG; Lluch-Hernández A; Rodriguez-Lescure A; Rodriguez-Sanchez C; Sanchez-Rovira P
Adv Ther; 2011 Dec; 28(12):1045-58. PubMed ID: 22068628
[TBL] [Abstract][Full Text] [Related]
29. Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.
Lintermans A; Van Asten K; Jongen L; Van Brussel T; Laenen A; Verhaeghe J; Vanderschueren D; Lambrechts D; Neven P
Eur J Cancer; 2016 Mar; 56():31-36. PubMed ID: 26798969
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea.
Beom SH; Oh J; Kim TY; Lee KH; Yang Y; Suh KJ; Moon HG; Han SW; Oh DY; Han W; Kim TY; Noh DY; Im SA
Cancer Res Treat; 2017 Apr; 49(2):454-463. PubMed ID: 27554482
[TBL] [Abstract][Full Text] [Related]
31. Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy.
Gallicchio L; Macdonald R; Wood B; Rushovich E; Helzlsouer KJ
Breast Cancer Res Treat; 2011 Nov; 130(2):569-77. PubMed ID: 21647676
[TBL] [Abstract][Full Text] [Related]
32. The discovery and mechanism of action of letrozole.
Bhatnagar AS
Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):7-17. PubMed ID: 17912633
[TBL] [Abstract][Full Text] [Related]
33. Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapy.
Otte JL; Flockhart D; Hayes D; Storniolo AM; Stearns V; Schneider B; Henry NL; Azzouz F; Nguyen A; Lemler S; Hayden J; Jeter S; Wright L; Carpenter JS
Menopause; 2009; 16(4):653-9. PubMed ID: 19455068
[TBL] [Abstract][Full Text] [Related]
34. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
Buzdar AU; Robertson JF; Eiermann W; Nabholtz JM
Cancer; 2002 Nov; 95(9):2006-16. PubMed ID: 12404296
[TBL] [Abstract][Full Text] [Related]
35. A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy.
Le Rhun E; Delbeuck X; Lefeuvre-Plesse C; Kramar A; Skrobala E; Pasquier F; Bonneterre J
Breast Cancer Res Treat; 2015 Aug; 152(3):569-80. PubMed ID: 26160250
[TBL] [Abstract][Full Text] [Related]
36. Emerging role of aromatase inhibitors in the adjuvant setting.
Goss PE
Am J Clin Oncol; 2003 Aug; 26(4):S27-33. PubMed ID: 12902874
[TBL] [Abstract][Full Text] [Related]
37. Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients.
Hertz DL; Henry NL; Rae JM
Pharmacogenomics; 2017 Apr; 18(5):481-499. PubMed ID: 28346074
[TBL] [Abstract][Full Text] [Related]
38. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
Thomsen KG; Lyng MB; Elias D; Vever H; Knoop AS; Lykkesfeldt AE; Lænkholm AV; Ditzel HJ
Breast Cancer Res Treat; 2015 Dec; 154(3):483-94. PubMed ID: 26585578
[TBL] [Abstract][Full Text] [Related]
39. Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data.
Ellis MJ; Rigden CE
Curr Med Res Opin; 2006 Dec; 22(12):2479-87. PubMed ID: 17257462
[TBL] [Abstract][Full Text] [Related]
40. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors.
Henry NL; Giles JT; Ang D; Mohan M; Dadabhoy D; Robarge J; Hayden J; Lemler S; Shahverdi K; Powers P; Li L; Flockhart D; Stearns V; Hayes DF; Storniolo AM; Clauw DJ
Breast Cancer Res Treat; 2008 Sep; 111(2):365-72. PubMed ID: 17922185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
